黄山胶囊(002817) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was CNY 379,891,008.70, representing an increase of 18.93% compared to CNY 319,426,287.89 in 2020[18]. - The net profit attributable to shareholders for 2021 was CNY 56,887,811.36, up 25.70% from CNY 45,255,710.15 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 48,301,265.66, reflecting a growth of 32.54% from CNY 36,442,844.58 in 2020[18]. - The net cash flow from operating activities increased by 37.28% to CNY 86,089,406.99, compared to CNY 62,711,557.61 in 2020[18]. - The total assets at the end of 2021 reached CNY 1,053,820,293.60, a 15.07% increase from CNY 915,812,091.29 at the end of 2020[18]. - The net assets attributable to shareholders were CNY 809,694,572.19, which is a 6.30% increase from CNY 761,707,349.51 in 2020[18]. - The basic earnings per share for 2021 were CNY 0.27, up 28.57% from CNY 0.21 in the previous year[18]. - The weighted average return on equity for 2021 was 7.25%, an increase from 6.10% in 2020[18]. Cash Flow and Investments - The net cash flow from operating activities improved by 37.28% to ¥86,089,406.99[60]. - The net cash flow generated from financing activities increased by CNY 36.76 million, a growth rate of 334.32%, primarily due to an increase in borrowings[61]. - The net increase in cash and cash equivalents was CNY 102.40 million, a rise of 195.87%, attributed to the increase in net cash flow from operating and financing activities[61]. - As of the end of 2021, cash and cash equivalents amounted to CNY 344.29 million, representing 32.67% of total assets, up from 26.43% at the beginning of the year[63]. - The company invested CNY 13.44 million in R&D, completing 9 technical innovations and filing 7 invention patents during the reporting period[44]. Market and Sales Performance - Domestic sales accounted for 96.90% of total revenue, while international sales surged by 360.62% to CNY 11.79 million[47]. - The company’s gelatin hollow capsules generated CNY 312.63 million in revenue, representing 82.29% of total sales, with a year-on-year growth of 20.59%[47]. - The sales volume of gelatin hollow capsules increased by 19.84% to 2,834,163.14 million units, while production volume rose by 30.81%[50]. - The company is actively expanding its market presence and strengthening cooperation with clients in the chemical drug procurement sector[34]. Research and Development - The company is committed to increasing R&D investment to enhance its competitive edge in the pharmaceutical technology service sector[41]. - The total number of R&D personnel increased by 18.06% to 85, enhancing the company's innovation capacity[58]. - The company has developed core technologies in enteric coating materials and hollow capsule production, securing several patents and industry recognitions[40]. Governance and Management - The company’s governance structure is in accordance with the requirements set by the China Securities Regulatory Commission, with independent operations of the board of directors and supervisory board[80]. - The company has established an independent financial department and accounting system, ensuring autonomous financial decision-making and compliance with tax obligations[86]. - The company has appointed independent directors with extensive backgrounds in finance and pharmaceuticals, enhancing governance[96]. - The company has a diverse board with members having backgrounds in engineering, economics, and pharmaceuticals, which supports its strategic direction[95]. Shareholder Engagement and Dividends - The company plans to distribute a cash dividend of CNY 0.80 per 10 shares, with a capital reserve conversion of 4 shares for every 10 shares held[4]. - The company implemented a cash dividend policy, distributing a total of 17,091,324.00 CNY, which represents 30.04% of the total profit distribution[118]. - The company’s profit distribution policy emphasizes reasonable, continuous, and stable returns to shareholders while considering long-term interests[116]. Risks and Challenges - The company faces risks related to regulatory changes in the pharmaceutical industry and fluctuations in raw material prices, particularly for gelatin used in capsules[75]. - The pharmaceutical industry is facing significant risks of product price reductions due to policies such as consistency evaluation of generic drugs and national volume-based procurement, leading to a decline in gross margins and increased competition[76]. Internal Controls and Compliance - The company reported no major or important internal control deficiencies during the reporting period, indicating effective internal control systems[122][124]. - The company has established a comprehensive internal control system that complies with relevant regulations and has been effectively implemented[122]. - The company maintained a continuous relationship with Tianjian Accounting Firm for 13 years, with an audit fee of 500,000 RMB for the current period[142]. Social Responsibility - The company actively engages in social responsibility initiatives, donating RMB 154,000 to charitable causes during the reporting period[131]. - The company has invested in environmental protection technologies, including a supercritical carbon dioxide system and a catalytic combustion system, to reduce emissions and energy consumption[131].